5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-[2-((cis)-2,6-Dimethyl-piperidin-1yl)-ethoxy]-benzyl}-1H-indole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-[2-((cis)-2,6-Dimethyl-piperidin-1yl)-ethoxy]-benzyl}-1H-indole
• 英文别名: 1-[[4-[2-(2,6-Dimethylpiperidin-1-yl)ethoxy]phenyl]methyl]-3-methyl-5-phenylmethoxy-2-(4-phenylmethoxyphenyl)indole
• 化学式: C₄₅H₄₈N₂O₃
• 分子量: 664.888
• InChiKey: CMLYALNDSRHGPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.3
• 重原子数：
  50
• 可旋转键数：
  13
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  35.9
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Methods of treating breast disorders
  申请人：American Home Products Corporation

  公开号：US20020016318A1

  公开（公告）日：2002-02-07

  This invention comprises methods of treating treatment of breast disorder comprising administration of a compound of the formulae I or II: 1 wherein Z is a moiety selected from the group of: 2 wherein: R 1 is selected from H, OH or the C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, or halogens; or C 1 -C 4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R 2 , R 3 , R 4 , R 5 , and R 6 are H, OH or C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, halogens, or C 1 -C 4 halogenated ethers, cyano, C 1 -C 6 alkyl, or trifluoromethyl, with the proviso that, when R 1 is H, R 2 is not OH; Y is the moiety: 3 R7 and R8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof.

  该发明涉及治疗乳腺疾病的方法，包括给予化合物I或II的治疗：其中Z是从以下组中选择的基团之一：其中：R1选自H、OH或其C1-C12酯或C1-C12烷基醚，或卤素；或C1-C4卤代醚包括三氟甲基醚和三氯甲基醚；R2、R3、R4、R5和R6是H、OH或其C1-C12酯或C1-C12烷基醚，卤素，或C1-C4卤代醚，氰基，C1-C6烷基，或三氟甲基，但当R1为H时，R2不是OH；Y是基团：R7和R8是烷基或连接在一起形成一个可选择取代的含氮环；或其药用盐。
• Combinations of bisphosphonates and estrogenic agents
  申请人：American Home Products Corporation

  公开号：US20020019373A1

  公开（公告）日：2002-02-14

  This invention comprises methods of treating bone disorders comprising administration of a bisphosphonate and compound of the formulae I or II: 1 wherein Z is a moiety selected from the group of: 2 wherein: R 1 is selected from H, OH or the C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, benzyloxy, or halogen; or C 1 -C 4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R 2 , R 3 , R 4 , R 5 , and R 6 are H, OH or C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, halogens, or C 1 -C 4 halogenated ethers, cyano, C 1 -C 6 alkyl, or trifluoromethyl, with the proviso that, when R 1 is H, R 2 is not OH; Y is the moiety: 3 R 7 and R 8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof.

  这项发明涵盖了治疗骨骼疾病的方法，包括给予双磷酸盐和式I或II的化合物：其中Z是从以下组中选择的一个基团：其中：R1选择自H、OH或其C1-C12酯或C1-C12烷基醚、苄氧基或卤素；或C1-C4卤代醚，包括三氟甲基醚和三氯甲基醚；R2、R3、R4、R5和R6是H、OH或其C1-C12酯或C1-C12烷基醚、卤素、或C1-C4卤代醚、氰基、C1-C6烷基或三氟甲基，但是当R1是H时，R2不是OH；Y是基团：R7和R8是烷基或连接在一起形成一个可选择取代的含氮环的；或其药用盐。
• Methods of inhibiting uterotrophic effects of estrogenic agents
  申请人：American Home Products Corporation

  公开号：US20020028805A1

  公开（公告）日：2002-03-07

  This invention comprises methods and pharmaceutical compositions for minimizing in a mammal the uterotrophic effect of a therapeutic compound selected from the group of tamoxifen, droloxifene, raloxifene, idoxifene, centrochroman, levor, meloxifene, TAT-59, GW 5838, or LY-353381 (?), comprising administration of a compound of the formulae I or II: 1 wherein: R 1 is selected from H, OH or the C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, or halogens; or C 1 -C 4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R 2 , R 3 , R 4 , R 5 , and R 6 are H, OH or C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, halogens, or C 1 -C 4 halogenated ethers, cyano, C 1 -C 6 alkyl, or trifluoromethyl, with the proviso that, when R 1 is H, R 2 is not OH; Y is the moiety: 2 R7 and R8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof.

  这项发明涉及用于减少哺乳动物体内治疗化合物（从酮甲环酯、多洛西芬、拉洛西芬、依多西芬、中环酮、左旋、美洛西芬、TAT-59、GW 5838或LY-353381（？）中选择的）子组中的子宫增生效应的方法和药物组合物，包括给予以下化合物的组合I或II的给药：1其中：R1选择自H、OH或其C1-C12酯或C1-C12烷基醚，或卤素；或C1-C4卤代醚，包括三氟甲基醚和三氯甲基醚；R2、R3、R4、R5和R6为H、OH或其C1-C12酯或C1-C12烷基醚，卤素，或C1-C4卤代醚，氰基，C1-C6烷基，或三氟甲基，但有条件地，当R1为H时，R2不是OH；Y是基团：2R7和R8是烷基或连接在一起形成一个可选择地取代的含氮环的；或其药学上可接受的盐。
• 2-phenyl-1- [4- (2-aminoethoxy) - benzyl] - indoles as estrogenic agents
  申请人：——

  公开号：US20010021719A1

  公开（公告）日：2001-09-13

  The present invention relates to new 2-Phenyl-1-[(2-Aminoethoxy)-Benzyl]-Indole compounds which are usefuil as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utiig these compounds, which have the general structures below: 1

  本发明涉及新的2-苯基-1-[(2-氨乙氧基)苄基]-吲哚化合物，其作为雌激素类药物有用，以及使用这些化合物的药物组合物和治疗方法，其通用结构如下：1
• 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
  申请人：Wyeth

  公开号：US20040110823A1

  公开（公告）日：2004-06-10

  The present invention relates to new 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below: 1

  本发明涉及新的2-苯基-1-[4-(2-氨基乙氧基)苯基]-吲哚化合物，其作为雌激素类药物有用，以及利用这些化合物的制药组合物和治疗方法，其具有以下一般结构式：1。